



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



SPDB-DM4

Cat. No.:	HY-12460
CAS No.:	1626359-62-3
Molecular Formula:	C ₄₆ H ₆₃ ClN ₄ O ₁₄ S ₂
Molecular Weight:	995.59
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-80°C, protect from light, stored under nitrogen



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (100.44 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.0044 mL	5.0221 mL	10.0443 mL
		5 mM		0.2009 mL	1.0044 mL	2.0089 mL
		10 mM		0.1004 mL	0.5022 mL	1.0044 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.51 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.51 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.51 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
IC ₅₀ & Target	Maytansinoids
In Vitro	Antibody-drug conjugates (ADCs) carry a highly potent small-molecule toxin covalently connected on the antibody via a proper linker. For therapeutic ADCs in cancer treatment, the antibody targets specific antigen of tumor cell surface with high binding affinity, thereafter the intact ADC was internalized into the tumor cells with the antigen and digested in the lysosome to release the antitumor toxin ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Puja Sapra, et al. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs. 2011 Aug;20(8):1131-49.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA